Observational studyCancer medicine2025
Evaluating Clinical and Sociodemographic Risk for Symptom Burden Associated Interference With Daily Functioning in the Primary Brain Tumor Patient Population.
Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03251989 (Exploring Outcomes and Risk in Patients With Rare Central Nervous System Tumors), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploring Outcomes and Risk in Patients With Rare Central Nervous System Tumors
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionSymptom burden associated with interference in daily functioning is worse in those with progression or higher-grade glial tumors. This exploratory study aims to identify factors associated with its severity in a diverse cross-sectional cohort of 566 brain tumor patients enrolled in a natural history study (NCT03251989, PI: T.S. Armstrong).
methodsSociodemographic and clinical data and self-reported activity-related interference (work, general activity, walking), mood-related interference (relations with others, enjoyment of life, mood) were reported via the MD Anderson Symptom Inventory-Brain Tumor. Activity and mood-related interference mean scores ≥ 2 were categorized as moderate-severe. Logistic regression assessed univariate associations with moderate-severe interference. Characteristics significant in the univariate analysis were included in a multivariable analysis.
resultsThis patient sample had a median age of 48 years (18-85), was mostly male (57%), with a high-grade tumor (73%), glioblastoma (39%), and tumor recurrence (49%). Risk factors for moderate-severe activity-related interference included: ≥ 2 surgeries (OR = 1.64, 95% CI [1.10, 2.44], p = 0.015), ependymoma (OR = 2.59, 95% CI [1.21-5.53], p = 0.014), and childhood in a rural area (OR = 1.74, 95% CI [1.15-2.63] p = 0.009). Risk factors for moderate-severe mood-related interference included tumor progression (OR = 2.02, 95% CI [1.21-3.36], p = 0.009).
conclusionPatient reported interference with daily physical functioning is associated with sociodemographic and disease-related characteristics and notably worse mood-related interference in those with progression. Future studies should include social determinants of health and change over time to identify and plan interventions for those at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.